Molbio Diagnostics Ltd. IPO

Incorporated in October 2000, Molbio Diagnostics Limited is a global point-of-care (POC) molecular diagnostics company engaged in the research, development, manufacturing, and commercialization of rapid diagnostic solutions for infectious and non-communicable diseases. The company has developed its proprietary ‘Truenat’ platform, a portable, battery-operated PCR-based molecular diagnostics system designed for resource-limited settings, offering accurate test results within an hour.

Molbio offers molecular testing solutions for over 30 diseases through 43 diagnostic assays, including tuberculosis (TB), COVID-19, HIV, Hepatitis B & C, and HPV. The company also provides radiology, digital pathology, and breast health screening solutions through its subsidiaries and strategic collaborations, while continuously expanding its diagnostics product pipeline through strong in-house R&D capabilities.

The company operates six manufacturing facilities across India and serves customers in over 90 countries, including government health programs, diagnostic laboratories, hospitals, and international healthcare organizations. Backed by a strong portfolio of patents, global certifications, and strategic acquisitions, Molbio has established itself as a leading innovator in molecular diagnostics.

As of March 31, 2026, the company employed 1,225 permanent employees across research & development, manufacturing, quality assurance, sales, finance, and corporate functions.

Strengths

  • Proprietary Truenat platform with WHO-endorsed TB molecular diagnostic technology.
  • Strong R&D capabilities supported by an extensive global patent portfolio.
  • Scalable business model with recurring revenues from diagnostic test kits.
  • Global presence across 90+ countries with strong government and institutional customer base.
  • Strategic acquisitions and collaborations expanding healthcare diagnostics portfolio.
  • Experienced management team with deep expertise in molecular diagnostics and healthcare innovation.

Company Financials (Restated)

Molbio Diagnostics Ltd.’s revenue increased by 42% and profit after tax (PAT) rose by 18% between the financial year ending with March 31, 2026 and March 31, 2025.

Period Ended31 Mar 202631 Mar 202531 Mar 2024
Assets2,148.421,461.561,221.06
Total Income1,455.171,027.94840.66
Profit After Tax164.14138.5883.54
EBITDA328.24256.64185.09
NET Worth1,144.68952.95807.94
Reserves and Surplus1,148.84990.84845.48
Total Borrowing412.64123.16174.58
Amount in ₹ Crore

IPO Objects of the Issue

The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:

#Issue ObjectsEst Amt (₹ Cr.)
1Funding capital expenditure towards the setting up of infrastructure for research and development facility, Center of Excellence and connected office space.125.12
2Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit, and80.81
3General Corporate Purposes 
 Total205.93

Key Performance Indicator (KPI)

KPIMar 31, 2026Mar 31, 2025
ROE15.59%16.20%
ROCE17.55%20.98%
RoNW14.55%15.23%
PAT Margin11.28%13.48%
EBITDA Margin22.56%24.97%
NAV101.5184.51
Price to Book Value 9.55

IPO Valuation

Valuation MetricPre IPOPost IPO
EPS (₹)14.5614.24
P/E (x)55.4356.67

Molbio Diagnostics IPO Details

IPO Date10 to 12 Aug, 2026
Listing DateMon, Aug 17, 2026
Face Value₹1 per share
Price Band₹768 to ₹807
Lot Size18 Shares
Sale TypeFresh capital cum OFS
Issue TypeBookbuilding IPO
Listing AtBSE, NSE
Employee Discount₹76.00
Total Issue Size1,16,46,246 shares
(agg. up to ₹940 Cr)
Fresh Issue24,80,246 shares
(agg. up to ₹200 Cr)
Offer for Sale91,66,000 shares of ₹1
(agg. up to ₹740 Cr)
Share Holding Pre Issue11,27,59,750 shares
Share Holding Post Issue11,52,39,996 shares

Molbio Diagnostics IPO Promoter Holding

The promoters of the company are Sriram Natarajan, Chandrasekhar Bhaskaran Nair, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram and Exxora Trading LLP

Share Holding Pre Issue44.89%
Share Holding Post Issue41.29%

SHARIAH SCREENING for - Molbio Diagnostics Ltd. IPO

BUSINESS SCREEN

FINANCIAL RATIOS

As per our analysis and Based on the information we have, this is the output.
Allah knows best.
If you find this result mistaken or questionable, let us know via email at info (@) halalstock.in

Spread the Knowledge - Share the Latest IPO Updates and Shariah Compliant IPO's.

Latest Current & Upcoming IPOs in BSE & NSE - Including Shariah Compliant.

The IPO dashboard offers insights on the Latest Current & Upcoming IPOs in BSE & NSE. It also evaluates IPOs for Shariah compliance, ensuring alignment with Islamic principles for ethical investment choices.

IPO

Shiprocket IPO Details

Last Updated on August 10, 2026 Shiprocket Ltd. IPO Incorporated in 2011, Shiprocket is an Indian e-commerce enablement company. It provides technology-driven solutions that help micro, small and medium enterprises

Read More »
IPO

Milky Mist Dairy Food IPO Details

Last Updated on August 10, 2026 Milky Mist Dairy Food Ltd. IPO Incorporated in July 2014, Milky Mist Dairy Food Limited is one of India’s fastest-growing packaged food companies focused

Read More »
IPO

Dhoot Transmission IPO Details

Last Updated on August 9, 2026 Dhoot Transmission Ltd. IPO Incorporated in April 1998, Dhoot Transmission Limited is one of India’s leading electrical and electronics (E&E) companies engaged in the

Read More »

Dear Halal Stock Users,

If you believe our website is a valuable resource,
we invite you to support us.
Your contribution ensures free access for all
and fuels future development.

You can contribute as little as
100, 200, 500 & so…
every bit counts.

Thank you for your support!